Physician profile
Gerald Lee
NPI 1942474648
$51,749.97
in general payments reported to CMS, 2019-2025
7 companies · $2,816 in 2025
The $2,816 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2021: $2,000 · 2022: $25K · 2023: $13K · 2024: $8,483 · 2025: $2,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $14K · Consulting Fee: $6,413 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $13,500.00 |
| Consulting Fee | $6,412.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $541.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25,027.24 | 2019-2022 | |
| Genzyme Corporation | $19,589.95 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $6,790.06 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $121.73 | 2025 | Albuterol Sulfate |
| Alk-Abello, INC | $118.68 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $80.30 | 2019-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $22.01 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.